Boehringer Ingelheim International Gmbh

Boehringer Ingelheim (canada) Ltd.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Eric Jolicoeur

Pierre Louis Beaulieu

Jean Rancourt

George Kukolj

James Gillard

Marc-André Poupart

Youla S Tsantrizos

Gulrez Fazal

Marc-Andre Poupart

Martin Poirier

Sylvie Goulet

Elisia Villemure

Carl Thibeault

Christian Brochu

Stephen Kawai

Simon Surprenant

Melissa Leblanc

Chantal Grand-Maitre

Oliver Hucke

Catherine Chabot

Cyrille Kuhn

Jean-Eric Lacoste

Steven LaPlante

René Coulombe

Anne Décor

Compounds of Formula (I) wherein R, R, R, R, Y, Zand Zare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: wherein Rand Rand Q are as defined herein;

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R, R, L, M, M, M, M, Y, Y, Z and Sp are as defined in claimor a salt thereof, as an inhibitor of HCV NS5B polymerase.

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein:

The HCV NS5B polymerase, when complexed with certain inhibitors, adopts a conformation in which the finger loop region defined by amino acid residues 18 to 35 is displaced to expose a binding pocket defined generally by amino acid residues 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 and 503. This newly exposed binding pocket defines a novel target in the search of further chemical entities which are capable of binding to HCV NS5B and modulating, or preferably inhibiting, the polymerase activity of HCV NS5B.

Hepatitis C Virus NS5B polymerase inhibitor binding pocket

Growing community of inventors

Laval, Canada

Eric Jolicoeur